Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Udaya Kompella to Animals

This is a "connection" page, showing publications Udaya Kompella has written about Animals.

 
Connection Strength
  
 
 
1.729
  
  1. Kompella UB. 2021 JOPT Award in Science: Dr. B?rbel Rohrer's Research on Mitochondria-Targeted Neuroprotective Drugs. J Ocul Pharmacol Ther. 2022 11; 38(9):591.
    View in: PubMed
    Score: 0.047
  2. Matter B, Bourne DWA, Kompella UB. A High-Throughput LC-MS/MS Method for the Simultaneous Quantification of Twenty-Seven Drug Molecules in Ocular Tissues. AAPS PharmSciTech. 2022 Jul 12; 23(6):192.
    View in: PubMed
    Score: 0.046
  3. Patil MA, Kompella UB. Noninvasive monitoring of suprachoroidal, subretinal, and intravitreal implants using confocal scanning laser ophthalmoscope (cSLO) and optical coherence tomography (OCT). Int J Pharm. 2021 Sep 05; 606:120887.
    View in: PubMed
    Score: 0.043
  4. Vooturi S, Bourne D, Panda JJ, Choi S, Kim H, Yandrapu SK, Kompella UB. Effect of Particle Size and Viscosity of Suspensions on Topical Ocular Bioavailability of Budesonide, a Corticosteroid. J Ocul Pharmacol Ther. 2020 Jul/Aug; 36(6):404-409.
    View in: PubMed
    Score: 0.040
  5. Patil MA, Kompella UB. Noninvasive Monitoring of Choroid-Retina Autofluorescence and Intravitreal Nanoparticle Disposition in Royal College of Surgeon Rats of Different Ages and Retinal Thinning. J Ocul Pharmacol Ther. 2020 Jul/Aug; 36(6):458-466.
    View in: PubMed
    Score: 0.040
  6. Kompella UB, Domb A, Urtti A, Jayagopal A, Wilson CG, Tang-Liu D. ISOPT Clinical Hot Topic Panel Discussion on Ocular Drug Delivery. J Ocul Pharmacol Ther. 2019 10; 35(8):457-465.
    View in: PubMed
    Score: 0.037
  7. Patil MA, Upadhyay AK, Hernandez-Lagunas L, Good R, Carpenter TC, Sucharov CC, Nozik-Grayck E, Kompella UB. Targeted delivery of YSA-functionalized and non-functionalized polymeric nanoparticles to injured pulmonary vasculature. Artif Cells Nanomed Biotechnol. 2018; 46(sup3):S1059-S1066.
    View in: PubMed
    Score: 0.036
  8. Hartman RR, Kompella UB. Intravitreal, Subretinal, and Suprachoroidal Injections: Evolution of Microneedles for Drug Delivery. J Ocul Pharmacol Ther. 2018 Jan/Feb; 34(1-2):141-153.
    View in: PubMed
    Score: 0.034
  9. Yandrapu SK, Upadhyay AK, Petrash JM, Kompella UB. Nanoparticles in porous microparticles prepared by supercritical infusion and pressure quench technology for sustained delivery of bevacizumab. Mol Pharm. 2013 Dec 02; 10(12):4676-86.
    View in: PubMed
    Score: 0.025
  10. Tyagi P, Barros M, Stansbury JW, Kompella UB. Light-activated, in situ forming gel for sustained suprachoroidal delivery of bevacizumab. Mol Pharm. 2013 Aug 05; 10(8):2858-67.
    View in: PubMed
    Score: 0.025
  11. Baid R, Upadhyay AK, Shinohara T, Kompella UB. Biosynthesis, characterization, and efficacy in retinal degenerative diseases of lens epithelium-derived growth factor fragment (LEDGF1-326), a novel therapeutic protein. J Biol Chem. 2013 Jun 14; 288(24):17372-83.
    View in: PubMed
    Score: 0.024
  12. Kompella UB, Amrite AC, Pacha Ravi R, Durazo SA. Nanomedicines for back of the eye drug delivery, gene delivery, and imaging. Prog Retin Eye Res. 2013 Sep; 36:172-98.
    View in: PubMed
    Score: 0.024
  13. Dhanda DS, Tyagi P, Mirvish SS, Kompella UB. Supercritical fluid technology based large porous celecoxib-PLGA microparticles do not induce pulmonary fibrosis and sustain drug delivery and efficacy for several weeks following a single dose. J Control Release. 2013 Jun 28; 168(3):239-50.
    View in: PubMed
    Score: 0.024
  14. Trivedi R, Redente EF, Thakur A, Riches DW, Kompella UB. Local delivery of biodegradable pirfenidone nanoparticles ameliorates bleomycin-induced pulmonary fibrosis in mice. Nanotechnology. 2012 Dec 21; 23(50):505101.
    View in: PubMed
    Score: 0.024
  15. Tyagi P, Kadam RS, Kompella UB. Comparison of suprachoroidal drug delivery with subconjunctival and intravitreal routes using noninvasive fluorophotometry. PLoS One. 2012; 7(10):e48188.
    View in: PubMed
    Score: 0.024
  16. Kadam RS, Scheinman RI, Kompella UB. Pigmented-MDCK (P-MDCK) cell line with tunable melanin expression: an in vitro model for the outer blood-retinal barrier. Mol Pharm. 2012 Nov 05; 9(11):3228-35.
    View in: PubMed
    Score: 0.024
  17. Yang H, Tyagi P, Kadam RS, Holden CA, Kompella UB. Hybrid dendrimer hydrogel/PLGA nanoparticle platform sustains drug delivery for one week and antiglaucoma effects for four days following one-time topical administration. ACS Nano. 2012 Sep 25; 6(9):7595-606.
    View in: PubMed
    Score: 0.023
  18. Kadam RS, Bourne DW, Kompella UB. Nano-advantage in enhanced drug delivery with biodegradable nanoparticles: contribution of reduced clearance. Drug Metab Dispos. 2012 Jul; 40(7):1380-8.
    View in: PubMed
    Score: 0.023
  19. Durairaj C, Chastain JE, Kompella UB. Intraocular distribution of melanin in human, monkey, rabbit, minipig and dog eyes. Exp Eye Res. 2012 May; 98:23-7.
    View in: PubMed
    Score: 0.023
  20. Durazo SA, Kompella UB. Functionalized nanosystems for targeted mitochondrial delivery. Mitochondrion. 2012 Mar; 12(2):190-201.
    View in: PubMed
    Score: 0.022
  21. Scheinman RI, Trivedi R, Vermillion S, Kompella UB. Functionalized STAT1 siRNA nanoparticles regress rheumatoid arthritis in a mouse model. Nanomedicine (Lond). 2011 Dec; 6(10):1669-82.
    View in: PubMed
    Score: 0.022
  22. Thakur A, Scheinman RI, Rao VR, Kompella UB. Pazopanib, a multitargeted tyrosine kinase inhibitor, reduces diabetic retinal vascular leukostasis and leakage. Microvasc Res. 2011 Nov; 82(3):346-50.
    View in: PubMed
    Score: 0.022
  23. Durazo SA, Kadam RS, Drechsel D, Patel M, Kompella UB. Brain mitochondrial drug delivery: influence of drug physicochemical properties. Pharm Res. 2011 Nov; 28(11):2833-47.
    View in: PubMed
    Score: 0.022
  24. Kadam RS, Jadhav G, Ogidigben M, Kompella UB. Ocular pharmacokinetics of dorzolamide and brinzolamide after single and multiple topical dosing: implications for effects on ocular blood flow. Drug Metab Dispos. 2011 Sep; 39(9):1529-37.
    View in: PubMed
    Score: 0.021
  25. Thakur A, Kadam R, Kompella UB. Trabecular meshwork and lens partitioning of corticosteroids: implications for elevated intraocular pressure and cataracts. Arch Ophthalmol. 2011 07; 129(7):914-20.
    View in: PubMed
    Score: 0.021
  26. Thakur A, Kadam RS, Kompella UB. Influence of drug solubility and lipophilicity on transscleral retinal delivery of six corticosteroids. Drug Metab Dispos. 2011 May; 39(5):771-81.
    View in: PubMed
    Score: 0.021
  27. Kompella UB, Kadam RS, Lee VH. Recent advances in ophthalmic drug delivery. Ther Deliv. 2010 Sep; 1(3):435-56.
    View in: PubMed
    Score: 0.020
  28. Durairaj C, Kadam RS, Chandler JW, Hutcherson SL, Kompella UB. Nanosized dendritic polyguanidilyated translocators for enhanced solubility, permeability, and delivery of gatifloxacin. Invest Ophthalmol Vis Sci. 2010 Nov; 51(11):5804-16.
    View in: PubMed
    Score: 0.020
  29. Rao VR, Prescott E, Shelke NB, Trivedi R, Thomas P, Struble C, Gadek T, O'Neill CA, Kompella UB. Delivery of SAR 1118 to the retina via ophthalmic drops and its effectiveness in a rat streptozotocin (STZ) model of diabetic retinopathy (DR). Invest Ophthalmol Vis Sci. 2010 Oct; 51(10):5198-204.
    View in: PubMed
    Score: 0.020
  30. Amrite A, Pugazhenthi V, Cheruvu N, Kompella U. Delivery of celecoxib for treating diseases of the eye: influence of pigment and diabetes. Expert Opin Drug Deliv. 2010 May; 7(5):631-45.
    View in: PubMed
    Score: 0.020
  31. Trivedi R, Kompella UB. Nanomicellar formulations for sustained drug delivery: strategies and underlying principles. Nanomedicine (Lond). 2010 Apr; 5(3):485-505.
    View in: PubMed
    Score: 0.020
  32. Sundaram S, Trivedi R, Durairaj C, Ramesh R, Ambati BK, Kompella UB. Targeted drug and gene delivery systems for lung cancer therapy. Clin Cancer Res. 2009 Dec 01; 15(23):7299-308.
    View in: PubMed
    Score: 0.019
  33. Sunkara G, Ayalasomayajula SP, DeRuiter J, Kompella UB. Probenecid treatment enhances retinal and brain delivery of N-4-benzoylaminophenylsulfonylglycine: an anionic aldose reductase inhibitor. Brain Res Bull. 2010 Feb 15; 81(2-3):327-32.
    View in: PubMed
    Score: 0.019
  34. Sundaram S, Roy SK, Ambati BK, Kompella UB. Surface-functionalized nanoparticles for targeted gene delivery across nasal respiratory epithelium. FASEB J. 2009 Nov; 23(11):3752-65.
    View in: PubMed
    Score: 0.019
  35. Durairaj C, Kim SJ, Edelhauser HF, Shah JC, Kompella UB. Influence of dosage form on the intravitreal pharmacokinetics of diclofenac. Invest Ophthalmol Vis Sci. 2009 Oct; 50(10):4887-97.
    View in: PubMed
    Score: 0.019
  36. Sundaram S, Durairaj C, Kadam R, Kompella UB. Luteinizing hormone-releasing hormone receptor-targeted deslorelin-docetaxel conjugate enhances efficacy of docetaxel in prostate cancer therapy. Mol Cancer Ther. 2009 Jun; 8(6):1655-65.
    View in: PubMed
    Score: 0.019
  37. Ayalasomayajula SP, Ashton P, Kompella UB. Fluocinolone inhibits VEGF expression via glucocorticoid receptor in human retinal pigment epithelial (ARPE-19) cells and TNF-alpha-induced angiogenesis in chick chorioallantoic membrane (CAM). J Ocul Pharmacol Ther. 2009 Apr; 25(2):97-103.
    View in: PubMed
    Score: 0.018
  38. Singh SR, Grossniklaus HE, Kang SJ, Edelhauser HF, Ambati BK, Kompella UB. Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV. Gene Ther. 2009 May; 16(5):645-59.
    View in: PubMed
    Score: 0.018
  39. Kadam RS, Kompella UB. Cassette analysis of eight beta-blockers in bovine eye sclera, choroid-RPE, retina, and vitreous by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Jan 15; 877(3):253-60.
    View in: PubMed
    Score: 0.018
  40. Cheruvu NP, Amrite AC, Kompella UB. Effect of diabetes on transscleral delivery of celecoxib. Pharm Res. 2009 Feb; 26(2):404-14.
    View in: PubMed
    Score: 0.018
  41. Sundaram S, Roy SK, Kompella UB. Differential expression of LHRH-receptor in bovine nasal tissue and its role in deslorelin delivery. Peptides. 2009 Feb; 30(2):351-8.
    View in: PubMed
    Score: 0.018
  42. Durairaj C, Shah JC, Senapati S, Kompella UB. Prediction of vitreal half-life based on drug physicochemical properties: quantitative structure-pharmacokinetic relationships (QSPKR). Pharm Res. 2009 May; 26(5):1236-60.
    View in: PubMed
    Score: 0.018
  43. Amrite AC, Edelhauser HF, Singh SR, Kompella UB. Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration. Mol Vis. 2008 Jan 29; 14:150-60.
    View in: PubMed
    Score: 0.017
  44. Amrite AC, Edelhauser HF, Kompella UB. Modeling of corneal and retinal pharmacokinetics after periocular drug administration. Invest Ophthalmol Vis Sci. 2008 Jan; 49(1):320-32.
    View in: PubMed
    Score: 0.017
  45. Cheruvu NP, Amrite AC, Kompella UB. Effect of eye pigmentation on transscleral drug delivery. Invest Ophthalmol Vis Sci. 2008 Jan; 49(1):333-41.
    View in: PubMed
    Score: 0.017
  46. Mo Y, Barnett ME, Takemoto D, Davidson H, Kompella UB. Human serum albumin nanoparticles for efficient delivery of Cu, Zn superoxide dismutase gene. Mol Vis. 2007 May 23; 13:746-57.
    View in: PubMed
    Score: 0.016
  47. Raghava S, Kompella UB. AQ4, an antitumor anthracenedione, inhibits endothelial cell proliferation and vascular endothelial growth factor secretion: implications for the therapy of ocular neovascular disorders. Eur J Pharmacol. 2007 Jul 30; 568(1-3):68-74.
    View in: PubMed
    Score: 0.016
  48. Kador PF, Randazzo J, Babb T, Koushik K, Takamura Y, Zhu W, Blessing K, Kompella UB. Topical aldose reductase inhibitor formulations for effective lens drug delivery in a rat model for sugar cataracts. J Ocul Pharmacol Ther. 2007 Apr; 23(2):116-23.
    View in: PubMed
    Score: 0.016
  49. Marra M, Gukasyan HJ, Raghava S, Kompella UB. 2nd Ophthalmic Drug Development and Delivery Summit. Expert Opin Drug Deliv. 2007 Jan; 4(1):77-85.
    View in: PubMed
    Score: 0.016
  50. Kompella UB, Sundaram S, Raghava S, Escobar ER. Luteinizing hormone-releasing hormone agonist and transferrin functionalizations enhance nanoparticle delivery in a novel bovine ex vivo eye model. Mol Vis. 2006 Oct 17; 12:1185-98.
    View in: PubMed
    Score: 0.016
  51. Cheruvu NP, Kompella UB. Bovine and porcine transscleral solute transport: influence of lipophilicity and the Choroid-Bruch's layer. Invest Ophthalmol Vis Sci. 2006 Oct; 47(10):4513-22.
    View in: PubMed
    Score: 0.016
  52. Amrite AC, Ayalasomayajula SP, Cheruvu NP, Kompella UB. Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage. Invest Ophthalmol Vis Sci. 2006 Mar; 47(3):1149-60.
    View in: PubMed
    Score: 0.015
  53. Amrite AC, Kompella UB. Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration. J Pharm Pharmacol. 2005 Dec; 57(12):1555-63.
    View in: PubMed
    Score: 0.015
  54. Bandi N, Ayalasomayajula SP, Dhanda DS, Iwakawa J, Cheng PW, Kompella UB. Intratracheal budesonide-poly(lactide-co-glycolide) microparticles reduce oxidative stress, VEGF expression, and vascular leakage in a benzo(a)pyrene-fed mouse model. J Pharm Pharmacol. 2005 Jul; 57(7):851-60.
    View in: PubMed
    Score: 0.014
  55. Ayalasomayajula SP, Kompella UB. Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model. Eur J Pharmacol. 2005 Mar 28; 511(2-3):191-8.
    View in: PubMed
    Score: 0.014
  56. Raghava S, Hammond M, Kompella UB. Periocular routes for retinal drug delivery. Expert Opin Drug Deliv. 2004 Nov; 1(1):99-114.
    View in: PubMed
    Score: 0.014
  57. Ayalasomayajula SP, Kompella UB. Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration. Pharm Res. 2004 Oct; 21(10):1797-804.
    View in: PubMed
    Score: 0.014
  58. Ayalasomayajula SP, Amrite AC, Kompella UB. Inhibition of cyclooxygenase-2, but not cyclooxygenase-1, reduces prostaglandin E2 secretion from diabetic rat retinas. Eur J Pharmacol. 2004 Sep 13; 498(1-3):275-8.
    View in: PubMed
    Score: 0.013
  59. Koushik KN, Kompella UB. Transport of deslorelin, an LHRH agonist, is vectorial and exhibits regional variation in excised bovine nasal tissue. J Pharm Pharmacol. 2004 Jul; 56(7):861-8.
    View in: PubMed
    Score: 0.013
  60. Koushik K, Dhanda DS, Cheruvu NP, Kompella UB. Pulmonary delivery of deslorelin: large-porous PLGA particles and HPbetaCD complexes. Pharm Res. 2004 Jul; 21(7):1119-26.
    View in: PubMed
    Score: 0.013
  61. Koushik K, Bandi N, Sundaram S, Kompella UB. Evidence for LHRH-receptor expression in human airway epithelial (Calu-3) cells and its role in the transport of an LHRH agonist. Pharm Res. 2004 Jun; 21(6):1034-46.
    View in: PubMed
    Score: 0.013
  62. Sunkara G, Ayalasomayajula SP, Rao CS, Vennerstrom JL, DeRuiter J, Kompella UB. Systemic and ocular pharmacokinetics of N-4-benzoylaminophenylsulfonylglycine (BAPSG), a novel aldose reductase inhibitor. J Pharm Pharmacol. 2004 Mar; 56(3):351-8.
    View in: PubMed
    Score: 0.013
  63. Koushik K, Kompella UB. Preparation of large porous deslorelin-PLGA microparticles with reduced residual solvent and cellular uptake using a supercritical carbon dioxide process. Pharm Res. 2004 Mar; 21(3):524-35.
    View in: PubMed
    Score: 0.013
  64. Clune S, Awolade P, Zhou Q, Esquer H, Matter B, Kearns JT, Kellett T, Akintayo DC, Kompella UB, LaBarbera DV. The validation of new CHD1L inhibitors as a therapeutic strategy for cancer. Biomed Pharmacother. 2024 Jan; 170:116037.
    View in: PubMed
    Score: 0.013
  65. Kompella UB, Bandi N, Ayalasomayajula SP. Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest Ophthalmol Vis Sci. 2003 Mar; 44(3):1192-201.
    View in: PubMed
    Score: 0.012
  66. Ayalasomayajula SP, Kompella UB. Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. Eur J Pharmacol. 2003 Jan 05; 458(3):283-9.
    View in: PubMed
    Score: 0.012
  67. Wenzel JG, Balaji KS, Koushik K, Navarre C, Duran SH, Rahe CH, Kompella UB. Pluronic F127 gel formulations of deslorelin and GnRH reduce drug degradation and sustain drug release and effect in cattle. J Control Release. 2002 Dec 13; 85(1-3):51-9.
    View in: PubMed
    Score: 0.012
  68. Aukunuru JV, Sunkara G, Ayalasomayajula SP, DeRuiter J, Clark RC, Kompella UB. A biodegradable injectable implant sustains systemic and ocular delivery of an aldose reductase inhibitor and ameliorates biochemical changes in a galactose-fed rat model for diabetic complications. Pharm Res. 2002 Mar; 19(3):278-85.
    View in: PubMed
    Score: 0.011
  69. Chalimeswamy A, Thanuja MY, Ranganath SH, Pandya K, Kompella UB, Srinivas SP. Oxidative Stress Induces a Breakdown of the Cytoskeleton and Tight Junctions of the Corneal Endothelial Cells. J Ocul Pharmacol Ther. 2022 Jan-Feb; 38(1):74-84.
    View in: PubMed
    Score: 0.011
  70. Kompella UB, Lee VH. Delivery systems for penetration enhancement of peptide and protein drugs: design considerations. Adv Drug Deliv Rev. 2001 Mar 01; 46(1-3):211-45.
    View in: PubMed
    Score: 0.011
  71. Sunkara G, Deruiter J, Clark CR, Kompella UB. In-vitro hydrolysis, permeability, and ocular uptake of prodrugs of N-[4-(benzoylamino)phenylsulfonyl]glycine, a novel aldose reductase inhibitor. J Pharm Pharmacol. 2000 Sep; 52(9):1113-22.
    View in: PubMed
    Score: 0.010
  72. Raol YH, Joksimovic SM, Sampath D, Matter BA, Lam PM, Kompella UB, Todorovic SM, Gonz?lez MI. The role of KCC2 in hyperexcitability of the neonatal brain. Neurosci Lett. 2020 11 01; 738:135324.
    View in: PubMed
    Score: 0.010
  73. Kompella UB, Sunkara G, Thomas E, Clark CR, Deruiter J. Rabbit corneal and conjunctival permeability of the novel aldose reductase inhibitors: N-[[4-(benzoylamino)phenyl] sulphonyl]glycines and N-benzoyl-N-phenylglycines. J Pharm Pharmacol. 1999 Aug; 51(8):921-7.
    View in: PubMed
    Score: 0.009
  74. Navarre CB, Zhang L, Sunkara G, Duran SH, Kompella UB. Ceftiofur distribution in plasma and joint fluid following regional limb injection in cattle. J Vet Pharmacol Ther. 1999 Feb; 22(1):13-9.
    View in: PubMed
    Score: 0.009
  75. Lenin R, Nagy PG, Alli S, Rao VR, Clauss MA, Kompella UB, Gangaraju R. Critical role of endoplasmic reticulum stress in chronic endothelial activation-induced visual deficits in tie2-tumor necrosis factor mice. J Cell Biochem. 2018 11; 119(10):8460-8471.
    View in: PubMed
    Score: 0.009
  76. Good RJ, Hernandez-Lagunas L, Allawzi A, Maltzahn JK, Vohwinkel CU, Upadhyay AK, Kompella UB, Birukov KG, Carpenter TC, Sucharov CC, Nozik-Grayck E. MicroRNA dysregulation in lung injury: the role of the miR-26a/EphA2 axis in regulation of endothelial permeability. Am J Physiol Lung Cell Mol Physiol. 2018 10 01; 315(4):L584-L594.
    View in: PubMed
    Score: 0.009
  77. Mathison S, Nagilla R, Kompella UB. Nasal route for direct delivery of solutes to the central nervous system: fact or fiction? J Drug Target. 1998; 5(6):415-41.
    View in: PubMed
    Score: 0.008
  78. Dani BA, Kompella UB. Inhibition of corneal metabolism of deslorelin by EDTA and ZnCl2. Drug Dev Ind Pharm. 1998 Jan; 24(1):11-7.
    View in: PubMed
    Score: 0.008
  79. Tran J, Craven C, Wabner K, Schmit J, Matter B, Kompella U, Grossniklaus HE, Olsen TW. A Pharmacodynamic Analysis of Choroidal Neovascularization in a Porcine Model Using Three Targeted Drugs. Invest Ophthalmol Vis Sci. 2017 07 01; 58(9):3732-3740.
    View in: PubMed
    Score: 0.008
  80. Muralidharan R, Babu A, Amreddy N, Srivastava A, Chen A, Zhao YD, Kompella UB, Munshi A, Ramesh R. Tumor-targeted Nanoparticle Delivery of HuR siRNA Inhibits Lung Tumor Growth In Vitro and In Vivo By Disrupting the Oncogenic Activity of the RNA-binding Protein HuR. Mol Cancer Ther. 2017 08; 16(8):1470-1486.
    View in: PubMed
    Score: 0.008
  81. Kompella UB, Dani BA. Metabolism of [des-Gly10, D-Trp6]LHRH ethylamide in the rabbit conjunctiva. J Ocul Pharmacol Ther. 1997 Apr; 13(2):163-70.
    View in: PubMed
    Score: 0.008
  82. Zhang X, Bohner A, Bhuvanagiri S, Uehara H, Upadhyay AK, Emerson LL, Bondalapati S, Muddana SK, Fang D, Li M, Sandhu Z, Hussain A, Carroll LS, Tiem M, Archer B, Kompella U, Patil R, Ambati BK. Targeted Intraceptor Nanoparticle for Neovascular Macular Degeneration: Preclinical Dose Optimization and Toxicology Assessment. Mol Ther. 2017 07 05; 25(7):1606-1615.
    View in: PubMed
    Score: 0.008
  83. Chaiyasan W, Praputbut S, Kompella UB, Srinivas SP, Tiyaboonchai W. Penetration of mucoadhesive chitosan-dextran sulfate nanoparticles into the porcine cornea. Colloids Surf B Biointerfaces. 2017 Jan 01; 149:288-296.
    View in: PubMed
    Score: 0.008
  84. Kompella UB, Dani BA. Metabolism of [Des-Gly10,D-Trp6]LHRH ethylamide in rabbit nasal tissue. Life Sci. 1996; 58(24):2201-7.
    View in: PubMed
    Score: 0.007
  85. Kompella UB, Kim KJ, Shiue MH, Lee VH. Cyclic AMP modulation of active ion transport in the pigmented rabbit conjunctiva. J Ocul Pharmacol Ther. 1996; 12(3):281-7.
    View in: PubMed
    Score: 0.007
  86. Lee JH, McBrayer MK, Wolfe DM, Haslett LJ, Kumar A, Sato Y, Lie PP, Mohan P, Coffey EE, Kompella U, Mitchell CH, Lloyd-Evans E, Nixon RA. Presenilin 1 Maintains Lysosomal Ca(2+) Homeostasis via TRPML1 by Regulating vATPase-Mediated Lysosome Acidification. Cell Rep. 2015 Sep 01; 12(9):1430-44.
    View in: PubMed
    Score: 0.007
  87. Wang Z, Cheng R, Lee K, Tyagi P, Ding L, Kompella UB, Chen J, Xu X, Ma JX. Nanoparticle-mediated expression of a Wnt pathway inhibitor ameliorates ocular neovascularization. Arterioscler Thromb Vasc Biol. 2015 Apr; 35(4):855-64.
    View in: PubMed
    Score: 0.007
  88. Kompella UB, Kim KJ, Shiue MH, Lee VH. Possible existence of Na(+)-coupled amino acid transport in the pigmented rabbit conjunctiva. Life Sci. 1995; 57(15):1427-31.
    View in: PubMed
    Score: 0.007
  89. Clapp T, Munks MW, Trivedi R, Kompella UB, Braun LJ. Freeze-thaw stress of Alhydrogel ? alone is sufficient to reduce the immunogenicity of a recombinant hepatitis B vaccine containing native antigen. Vaccine. 2014 Jun 24; 32(30):3765-71.
    View in: PubMed
    Score: 0.007
  90. Rajashekhar G, Shivanna M, Kompella UB, Wang Y, Srinivas SP. Role of MMP-9 in the breakdown of barrier integrity of the corneal endothelium in response to TNF-a. Exp Eye Res. 2014 May; 122:77-85.
    View in: PubMed
    Score: 0.007
  91. Kim SJ, Toma H, Shah R, Kompella UB, Vooturi SK, Sheng J. The safety, pharmacokinetics, and efficacy of intraocular celecoxib. Invest Ophthalmol Vis Sci. 2014 Mar 10; 55(3):1409-18.
    View in: PubMed
    Score: 0.006
  92. Cruz NM, Yuan Y, Leehy BD, Baid R, Kompella U, DeAngelis MM, Escher P, Haider NB. Modifier genes as therapeutics: the nuclear hormone receptor Rev Erb alpha (Nr1d1) rescues Nr2e3 associated retinal disease. PLoS One. 2014; 9(1):e87942.
    View in: PubMed
    Score: 0.006
  93. Kompella UB, Kim KJ, Lee VH. Active chloride transport in the pigmented rabbit conjunctiva. Curr Eye Res. 1993 Dec; 12(12):1041-8.
    View in: PubMed
    Score: 0.006
  94. Tari SR, Youssif M, Samson CM, Harris RL, Lin CM, Kompella UB, Antonetti DA, Barile GR. Polychromatic angiography for the assessment of VEGF-induced BRB dysfunction in the rabbit retina. Invest Ophthalmol Vis Sci. 2013 Aug 15; 54(8):5550-8.
    View in: PubMed
    Score: 0.006
  95. Chowdhury S, Guha R, Trivedi R, Kompella UB, Konar A, Hazra S. Pirfenidone nanoparticles improve corneal wound healing and prevent scarring following alkali burn. PLoS One. 2013; 8(8):e70528.
    View in: PubMed
    Score: 0.006
  96. Bargagna-Mohan P, Deokule SP, Thompson K, Wizeman J, Srinivasan C, Vooturi S, Kompella UB, Mohan R. Withaferin A effectively targets soluble vimentin in the glaucoma filtration surgical model of fibrosis. PLoS One. 2013; 8(5):e63881.
    View in: PubMed
    Score: 0.006
  97. Luo L, Zhang X, Hirano Y, Tyagi P, Barab?s P, Uehara H, Miya TR, Singh N, Archer B, Qazi Y, Jackman K, Das SK, Olsen T, Chennamaneni SR, Stagg BC, Ahmed F, Emerson L, Zygmunt K, Whitaker R, Mamalis C, Huang W, Gao G, Srinivas SP, Krizaj D, Baffi J, Ambati J, Kompella UB, Ambati BK. Targeted intraceptor nanoparticle therapy reduces angiogenesis and fibrosis in primate and murine macular degeneration. ACS Nano. 2013 Apr 23; 7(4):3264-75.
    View in: PubMed
    Score: 0.006
  98. Baltazar GC, Guha S, Lu W, Lim J, Boesze-Battaglia K, Laties AM, Tyagi P, Kompella UB, Mitchell CH. Acidic nanoparticles are trafficked to lysosomes and restore an acidic lysosomal pH and degradative function to compromised ARPE-19 cells. PLoS One. 2012; 7(12):e49635.
    View in: PubMed
    Score: 0.006
  99. Tewari-Singh N, Jain AK, Inturi S, Ammar DA, Agarwal C, Tyagi P, Kompella UB, Enzenauer RW, Petrash JM, Agarwal R. Silibinin, dexamethasone, and doxycycline as potential therapeutic agents for treating vesicant-inflicted ocular injuries. Toxicol Appl Pharmacol. 2012 Oct 01; 264(1):23-31.
    View in: PubMed
    Score: 0.006
  100. Qazi Y, Stagg B, Singh N, Singh S, Zhang X, Luo L, Simonis J, Kompella UB, Ambati BK. Nanoparticle-mediated delivery of shRNA.VEGF-a plasmids regresses corneal neovascularization. Invest Ophthalmol Vis Sci. 2012 May 14; 53(6):2837-44.
    View in: PubMed
    Score: 0.006
  101. Cho YK, Uehara H, Young JR, Tyagi P, Kompella UB, Zhang X, Luo L, Singh N, Archer B, Ambati BK. Flt23k nanoparticles offer additive benefit in graft survival and anti-angiogenic effects when combined with triamcinolone. Invest Ophthalmol Vis Sci. 2012 Apr 30; 53(4):2328-36.
    View in: PubMed
    Score: 0.006
  102. Holden CA, Tyagi P, Thakur A, Kadam R, Jadhav G, Kompella UB, Yang H. Polyamidoamine dendrimer hydrogel for enhanced delivery of antiglaucoma drugs. Nanomedicine. 2012 Jul; 8(5):776-83.
    View in: PubMed
    Score: 0.005
  103. Jin J, Zhou KK, Park K, Hu Y, Xu X, Zheng Z, Tyagi P, Kompella UB, Ma JX. Anti-inflammatory and antiangiogenic effects of nanoparticle-mediated delivery of a natural angiogenic inhibitor. Invest Ophthalmol Vis Sci. 2011 Aug 05; 52(9):6230-7.
    View in: PubMed
    Score: 0.005
  104. Vasireddy V, Chavali VR, Joseph VT, Kadam R, Lin JH, Jamison JA, Kompella UB, Reddy GB, Ayyagari R. Rescue of photoreceptor degeneration by curcumin in transgenic rats with P23H rhodopsin mutation. PLoS One. 2011; 6(6):e21193.
    View in: PubMed
    Score: 0.005
  105. Pan CK, Durairaj C, Kompella UB, Agwu O, Oliver SC, Quiroz-Mercado H, Mandava N, Olson JL. Comparison of long-acting bevacizumab formulations in the treatment of choroidal neovascularization in a rat model. J Ocul Pharmacol Ther. 2011 Jun; 27(3):219-24.
    View in: PubMed
    Score: 0.005
  106. Pfeifer T, Buchebner M, Chandak PG, Patankar J, Kratzer A, Obrowsky S, Rechberger GN, Kadam RS, Kompella UB, Kostner GM, Kratky D, Levak-Frank S. Synthetic LXR agonist suppresses endogenous cholesterol biosynthesis and efficiently lowers plasma cholesterol. Curr Pharm Biotechnol. 2011 Feb 01; 12(2):285-92.
    View in: PubMed
    Score: 0.005
  107. Lee VH, Yamamoto A, Kompella UB. Mucosal penetration enhancers for facilitation of peptide and protein drug absorption. Crit Rev Ther Drug Carrier Syst. 1991; 8(2):91-192.
    View in: PubMed
    Score: 0.005
  108. Missel P, Chastain J, Mitra A, Kompella U, Kansara V, Duvvuri S, Amrite A, Cheruvu N. In vitro transport and partitioning of AL-4940, active metabolite of angiostatic agent anecortave acetate, in ocular tissues of the posterior segment. J Ocul Pharmacol Ther. 2010 Apr; 26(2):137-46.
    View in: PubMed
    Score: 0.005
  109. Kang SJ, Durairaj C, Kompella UB, O'Brien JM, Grossniklaus HE. Subconjunctival nanoparticle carboplatin in the treatment of murine retinoblastoma. Arch Ophthalmol. 2009 Aug; 127(8):1043-7.
    View in: PubMed
    Score: 0.005
  110. Bara?ano DE, Kim SJ, Edelhauser HF, Durairaj C, Kompella UB, Handa JT. Efficacy and pharmacokinetics of intravitreal non-steroidal anti-inflammatory drugs for intraocular inflammation. Br J Ophthalmol. 2009 Oct; 93(10):1387-90.
    View in: PubMed
    Score: 0.005
  111. Park K, Chen Y, Hu Y, Mayo AS, Kompella UB, Longeras R, Ma JX. Nanoparticle-mediated expression of an angiogenic inhibitor ameliorates ischemia-induced retinal neovascularization and diabetes-induced retinal vascular leakage. Diabetes. 2009 Aug; 58(8):1902-13.
    View in: PubMed
    Score: 0.005
  112. Kratzer A, Buchebner M, Pfeifer T, Becker TM, Uray G, Miyazaki M, Miyazaki-Anzai S, Ebner B, Chandak PG, Kadam RS, Calayir E, Rathke N, Ahammer H, Radovic B, Trauner M, Hoefler G, Kompella UB, Fauler G, Levi M, Levak-Frank S, Kostner GM, Kratky D. Synthetic LXR agonist attenuates plaque formation in apoE-/- mice without inducing liver steatosis and hypertriglyceridemia. J Lipid Res. 2009 Feb; 50(2):312-26.
    View in: PubMed
    Score: 0.004
  113. Jani PD, Singh N, Jenkins C, Raghava S, Mo Y, Amin S, Kompella UB, Ambati BK. Nanoparticles sustain expression of Flt intraceptors in the cornea and inhibit injury-induced corneal angiogenesis. Invest Ophthalmol Vis Sci. 2007 May; 48(5):2030-6.
    View in: PubMed
    Score: 0.004
  114. Margalit E, Kugler LJ, Brumm MV, Meza JL, Kompella UB, Escobar ER, Christensen GR. The safety of intraocular ketorolac in rabbits. Invest Ophthalmol Vis Sci. 2006 May; 47(5):2093-9.
    View in: PubMed
    Score: 0.004
  115. Hosoya K, Kompella UB, Kim KJ, Lee VH. Contribution of Na(+)-glucose cotransport to the short-circuit current in the pigmented rabbit conjunctiva. Curr Eye Res. 1996 Apr; 15(4):447-51.
    View in: PubMed
    Score: 0.002
  116. Lee YH, Kompella UB, Lee VH. Systemic absorption pathways of topically applied beta adrenergic antagonists in the pigmented rabbit. Exp Eye Res. 1993 Sep; 57(3):341-9.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)